Tubal ligation results in less advanced stages and lower risk of metastatic spread at diagnosis of endometrial cancer (EC) but the primary preventive effect of the procedure is unclear. In a Swedish nationwide population-based cohort study, we crosslinked registry data for tubal ligation, EC, and death for Swedish women between 1973 and 2010. All women were followed until EC, emigration, hysterectomy for non-cancerous reasons, death, or end of follow-up. Primary outcome was incidence of EC and secondary outcome overall survival. We calculated adjusted incidence rates (IR) per 100,000 person-years and hazard ratios (HR) using Cox regression models. A total of 35,711 cases of EC were identified among 5,385,186 women. The IR of EC among exposed was 17.7 (95% CI 15.7-19.9) versus 29.0 (95% CI 28.7-29.3) among unexposed (per 100,000 women years). Exposed individuals had significantly reduced risk of EC (HR 0.73, 95% CI 0.65-0.83). The mortality rate among women with EC was 72% lower in exposed compared to unexposed (IR 1,441; 95% CI 1,089-1,907 and IR 5,136; 95% CI 5,065-5,209, respectively) which following adjustment corresponded to a HR of 0.71 (95% CI 0.49-1.03). Tubal ligation was associated with lower risk of EC as well as mortality rates in women with EC. Elective tubal ligation may be adopted in future cancer preventive strategies but must be balanced against the irreversibility of the procedure, which preclude further unassisted reproduction.
Introduction
Endometrial cancer (EC) is the most common gynecological cancer and the sixth most common cancer overall among women worldwide. 1 The incidence of EC, of which endometrioid adenocarcinoma is the most common subtype, is rising in industrialized countries. 2 About 400,000 women are living with EC in Europe and 320,000 new cases were diagnosed worldwide in 2012. 1, 3 Therefore, novel strategies and approaches in EC prevention could have significant public health implications.
Emerging evidence suggest that having had a tubal ligation is associated with less advanced stages as well as lower risk of intraperitoneal metastatic spread at diagnosis of EC. 4, 5 Female sterilization remains the most common contraceptive method worldwide but the prevalence varies widely with almost 22% in the US and <10% in Europe. 6 Hypothetically, the procedure may decrease the risk of EC by preventing spread of premalignant or malignant epithelial cells from the Fallopian tubes to the intrauterine cavity. However, results from previous studies relating tubal ligation to subsequent risk of EC are inconclusive. [7] [8] [9] This inconsistency could be attributed to a lack of true association or methodological limitations including self-reported ascertainment of exposure 7, 9 and insufficient number of cases. 8 Therefore, we performed a large scale study using prospectively collected and uniformly classified data from nationwide Swedish registries to determine the influence of tubal ligation on EC incidence and mortality in the general population.
Methods

Data sources
We used independently collected data from nationwide healthcare registers supervised by the Swedish Board of Health and Welfare (http://www.socialstyrelsen.se/english). Register linkage based on the individually unique national registration number, assigned to all nationals at birth or immigration, was used to ascertain information on exposures and outcomes. Exposed women were identified using the Swedish Patient Register, established in 1964, which contains data on individual hospital discharges including date and discharge diagnoses according to the International Classification of Diseases (ICD) versions 7 through 10 as well as operation codes according to the Swedish Classification of Operations and Major Procedures. Correct coding for surgical procedures is achieved in 98% of cases. 10 Incident cases of primary EC were identified in the Swedish Cancer Register. The register, established in 1958, includes histologically verified incident cancers, is >95% complete and is uniformly classified according to ICD-7. Classification of tumor morphology according to the Systematized Nomenclature of Medicine (SNOMED) is available from 1993. Using national registration numbers all individual records were also linked with the Cause of Death Register, the Swedish Medical Birth Register, the Swedish Education Registry, the Pharmaceutical Register and the Population Register. The study was approved by the Research Ethics Committee at Karolinska Institutet, Stockholm, Sweden, and conforms to the STROBE guidelines for reporting observational studies (www.strobestatement.org).
Study design
From the Population Register, we identified all women above 18 years of age in-between January 1, 1973 and December 31, 2009 (n 5 5,704,154). Based on the Inpatient Register, our exposure was defined as tubal ligation (operation codes 7150, 7151, 7152 for 1973-1996 and LGA00, LGA10, LGA11, LGA20-22, LGA96-98 for 1997-2009) with date of surgery used as time of exposure. From SNOMED, code M81403 was used to determine "adenocarcinoma NOS" (not otherwise specified) and all reminding morphology codes (except for sarcomas) were used to identify non-endometrioid cancers. Based on the Cancer Register, our main outcome measure was identified by a diagnosis of primary EC (ICD-7 codes 172.0 and 172.1).
Women were excluded from analysis if they had a hysterectomy before entering the cohort (n 5 2,947), if they had any primary cancer before entering the cohort (n 5 76,416), if they had other inconsistencies of their data (n 5 14,635) and if they emigrated out of Sweden before entering the cohort (n 5 224,970).
The follow-up of each woman was divided into two periods: unexposed and exposed. Women contributed persontime to the study as unexposed unless they underwent tubal ligation from which time they contributed person-time as exposed throughout the observational period. For exposed and unexposed alike the end of follow-up was the first occurrence of EC, any other cancer, death, emigration, hysterectomy or end of the observational period (December 31, 2009). Cases of EC diagnosed within 1 year from exposure were considered to occur in the unexposed period. For the subanalysis on tumor morphology, the study period was limited to the calendar years 1993-2009. We also studied the mortality risk among EC patients in relation to tubal ligation. The exposure was tubal ligation versus not having had a tubal ligation before cancer diagnosis and covariates included parity before cancer diagnosis, educational level and calendar year and age. For the mortality analysis end of follow-up was the first occurrence of death, emigration or end of the observational period (December 31, 2010).
Data analysis
We calculated incidence rates (IRs) of EC as the number of cases per 100,000 person-years. Cox proportional hazard models were used to estimate the hazard ratios (HRs) for EC during the exposed versus unexposed periods, where the time scale of interest is the time since exposure. Adjustment was made for age, calendar year and parity (categorized as: nulliparous; 1-2 childbirths; and >3 childbirths) and educational level (categorized as: high: college or university studies; middle: attended high school; and low: only secondary school). Age, calendar year and parity were modeled as timedependent variables, where age was divided into 5-year intervals; calendar year was divided into 15-year periods and parity according to age intervals.
To evaluate the influence of diabetes on the association between tubal ligation and EC, we conducted a multivariate sensitivity analysis restricted to calendar years 1987-2009 during which information on diabetes was available in the Patient register. Information on use of oral contraceptives and hormone replacement therapy (HRT) from the Pharmaceutical Register was available from July 1, 2005 until December 31, 2009. As a consequence, we could not determine how
What's new?
Tubal ligation is associated with lower stage and reduced mortality among women with endometrial cancer. Whether tubal ligation has subsequent effects on endometrial cancer risk, however, remains unclear. In this population-based study of women in Sweden, tubal ligation was associated with a significantly decreased risk of subsequent development of endometrial cancer, as well as with reduced mortality from the disease. The effect was most evident for aggressive tumors. The findings suggest that tubal ligation constitutes an effective measure for the prevention of endometrial cancer, especially in high-risk populations, though the mechanism behind the association remains unknown. exogenous hormone use prior or subsequent to tubal ligation influenced the association with EC in a multivariate setting. To evaluate the influence of oral contraception and HRT on the association, we instead examined proportions of first-time users among exposed and unexposed women 2008 and 2009.
Cox proportional hazard models were used to estimate the HR for death among exposed versus unexposed women with EC using age as the time scale. In all Cox models, the proportional hazards assumption was checked graphically and by Schoenfeld's partial residuals; neither of them revealed any indication of violation of this assumption. Two-tailed 95% confidence intervals and p-values were given, with p < 0.05 regarded as significant. The statistical software package SAS 9.2 (SAS Institute Inc., Cary, NC) was used for all analyses.
Results
After exclusions, the final study population included 5,385,186 women of which 80,765 women had undergone tubal ligation (1.50%). During follow-up, encompassing a total of 123,662,155 person-years at risk, there were 35,711 cases of primary EC among women with no prior cancer diagnosis. Table 1 shows demographic characteristics of exposed and unexposed. Table 2 shows the IRs for tubal ligation and EC. Among the 35,711 cases of EC, 281 cases occurred among the exposed and 35,430 cases among the unexposed women. The overall IRs per 100,000 women years of EC were 17.7 for women with previous tubal ligation and 29.0 for women with surgically non-obstructed tubes. This corresponded to an incidence reduction in 41.4% among women having had a tubal ligation in relation to unexposed women.
The overall HR for EC among exposed versus unexposed is presented in Table 2 and the HR over time since exposure in Table 3 . Tubal ligation was associated with a significantly reduced risk of EC (HR 0.73, 95% CI 0.65-0.83). When the effect of exposure time was considered, tubal ligation was associated with a significantly reduced risk of EC 10 years or more after surgery (HR 0.74, 95% CI 0.65-0.84). Heterogeneity test demonstrated that HRs differed significantly between the 0-4 and 5-9 periods and between the 5-9 and 101 periods (p 5 0.026 and p 5 0.03 respectively). The risk of EC was near identical with or without adjustment of diabetes (HR 0.71, 95% CI 0.63-0.80 versus HR 0.71, 95% CI 0.63-0.81) suggesting that diabetes did not confound the association. The proportions of women using hormones (oral contraceptives, HRT) in conjunction with tubal ligation was essentially the same (given 5-year intervals) as women of corresponding age not having tubal surgery, suggesting that their uses did not confound the association (Table 1) . Table 4 presents descriptive histomorphology and HRs in women having had tubal ligation in relation to unexposed. Information on pathological-anatomical-diagnosis according to SNOMED was available in a total of 18,684 of diagnosed EC s. A total of 17,149 (92%) of our EC cases were classified as adenocarcinoma NOS (not otherwise specified) with 253/ 259 (98%) and 16,896/18,425 (92%) cases among exposed and unexposed, respectively. The remainder was classified as non-endometrioid carcinoma with six cases among women with a history of tubal ligation. Tubal ligation was inversely associated with EC of both adenocarcinoma NOS and nonendometrioid morphology (HR 0.78, 95% CI 0.68-0.88; HR 0.25, 95% CI 0.11-0.57, respectively). Heterogeneity test for non-endometrioid versus NOS showed that the HRs differed significantly (p 5 0.020). The small number of nonendometrioid cancers among women with previous tubal ligation precluded sub-analyses for specific morphologies. Among EC patients with a tubal ligation, the mortality rate per 100,000 women years was 1,207 (95% CI 839-1,737) as compared to 5,128 (95% CI 5,057-5,200) among EC patients with intact Fallopian tubes. This corresponded to a 72% absolute reduction in the EC related mortality rate. There was an inverse association between tubal ligation and mortality risk among EC patients, although not statistically significant (HR 0.71, 95% CI 0.49-1.03).
Discussion
We previously reported that salpingectomy is associated with a reduced risk of serous ovarian cancer. 11 In our study, we
show that tubal ligation is associated with a decreased incidence of EC and related mortality. These combined findings may signify important public health implications indicating that elective ligation, or removal, of the Fallopian tubes may significantly decrease the risk of the two of the most common gynecological cancers. In lieu of effective primary prevention strategies, performing a salpingectomy or tubal ligation at the time of cesarean section or other abdominal surgery offers a prevention strategy that may decrease future risk of reproductive organ carcinoma. When counseling patients this benefit must be balanced against the surgical risks and irreversibility of the procedure, which preclude future unassisted reproduction. We found a clear association between tubal ligation and a lower overall incidence of EC. 7, 9 Simply put our data suggest that over a decade, one in 294 sterilized women will develop EC compared to one out of 172 women with non-obstructed Fallopian tubes. Occlusion of the Fallopian tubes could potentially interfere with endometrial carcinogenesis in several ways. It has been suggested that tubal ligation affects ovarian blood supply with a subsequent impact on estradiol production. 12 However, recent publications contradict older data showing intact ovarian function after tubal ligation. 13, 14 EC is traditionally divided into Types I and II diseases based on morphology. 15 The latter comprises uterine clear cell and serous carcinomas (USC) and may be difficult, if not impossible, to distinguish from ovarian cancer with similar histology. USC shares molecular and morphologic similarities with high-grade serous ovarian cancer and supposedly arises from premalignant cells (endometrial intraepithelial carcinoma, EIC) within the endometrial epithelium. 16, 17 However, the origin of serous pelvic carcinomas is debated and a monoclonal origin was suggested >20 years ago. 18 Mutation analysis of coexisting tubal and endometrial serous disease suggest that a subset of USC Abbreviations: HR: hazard ratios; NOS: not otherwise specified. 1 Person-years are the same for total, NOS and non-endometrioid. 2 Adjusted for age, calendar year, parity and education status.
arise in the fallopian tubes. [19] [20] [21] This is further supported by our analysis of tumor morphology, showing that the association was most pronounced for non-endometrioid tumors.
Sub-analyses from the Women's Health Initiative and the Million Women Study have failed to demonstrate an association between tubal ligation and EC. 7, 9 Both of these trials excluded women below 50 years of age and relied on selfreported information on both exposure (tubal ligation) and to some extent the outcome (EC). It is reasonable to assume that these potential sources of selection and reporting bias may have influenced the analyses. Retrospective studies have shown that tubal ligation influences metastatic spread and mortality among patients with endometrial carcinoma but have not addressed the primary preventive effect of tubal ligation per se. 4, 5 Using prospectively collected data from independent registers prevented recall bias, whereas the near complete registration of the exposure as well as censoring at the time of hysterectomy reduced the risk of reporting and misclassification bias. We used censoring also to remove unknown sources of confounding such as the association between tubal ligation and other malignancies as well as other types of surgery. Detection bias was limited by censoring women during the first year after tubal ligation. Other strengths of our study include the homogenous classification of exposure and outcome as well as the very large study population. The decision to undergo tubal sterilization is influenced by multiple factors. We were able to control for age, educational level and parity, which have been identified as determinants for tubal ligation. 22 The Swedish nationwide healthcare registers do not collect data on weight changes over time for the population. Therefore, we could not directly assess the effect of body mass index (BMI) on the association. However, adjusting the analysis for educational attainment can to some extent be considered an effective proxy for socioeconomic status, smoking and obesity which have been associated with EC. [23] [24] [25] Furthermore, demographic data from the Women's Health Initiative and the Million Women Study showed similar BMI between women with and without a history of tubal ligation. 7, 9 Thus, it is unlikely that the observed association was attributed to significantly lower BMI among sterilized women. In addition, a sensitivity analysis showed that diabetes, which is a known risk factor for EC, had no significant influence on the association between tubal ligation and EC.
Nonetheless, we lacked detailed information on some potential co-morbidities and life-style factors that could be associated with EC. Most importantly information on use of oral contraceptives and HRT was limited and available only for the last 5 years of the study observational period. Therefore, we could not assess the direct influence of exogenous hormone use on the association, which to some extent may have resulted in residual confounding. However, the near identical prescription patterns prior (contraceptives) or subsequent (HRT) to surgery suggest that residual confounding is limited.
In our study, the mortality rate was markedly lower in women with tubal ligation and a subsequent diagnosis of EC as compared to women with intact Fallopian tubes. However, the inverse association with cancer related mortality did not reach significance in multivariate regression analysis adjusted for age. The reason for this is probably due to the insufficient duration of follow-up for women having had surgery during the last two decades of the observational period (when laparoscopy became widely available) and the young age at which surgery is done. An inverse relation with cancer specific mortality also substantiates repeat findings of lower EC stages at the time of diagnosis in women with a prior tubal ligation. 4, 5 To summarize, occlusion of the Fallopian tubes was associated with a reduction in incident EC. Given the limitations of our study, our findings need to be further validated before the practice of tubal ligation can be adopted as a prevention strategy for EC.
